Last
Update:
May 19, 2013
Documents identified with this icon are in Portable Document Format (PDF)
and require the
Adobe
Acrobat Reader
Journal
Papers, Abstracts, and Commentaries
| |
A review of pharmacological interactions between HIV or
hepatitis C virus medications and opioid agonist therapy: implications and
management for clinical practice.
Bruce RD, Moody DE, Altice FL,
et al
Expert Rev Clin Pharmacol. 2013
May;6(3):249-69.
Abstract
Earlier Sustained Virologic Response Endpoints for Regulatory Approval and Dose
Selection of Hepatitis C Therapies.
Chen J, Florian J, Carter W, Fleischer RD,
et al
Gastroenterology.
2013 Mar 4.
Abstract |
| |
A Survey of Hepatitis C Treatment Clinical Practice Patterns
Using the Newly Approved Protease Inhibitors.
Chen EY, Lee WM, Hynan LS, Singal AG.
J Clin Gastroenterol. 2013 Mar
.
Abstract |
A Survey of Hepatitis C Treatment Clinical Practice Patterns
Using the Newly Approved Protease Inhibitors.
Chen EY, Lee WM, Hynan LS, Singal AG.
J Clin Gastroenterol. 2013 Mar
.
Abstract
Antiviral resistance and direct-acting antiviral agents for HCV.
Aloia AL, Locarnini S, Beard MR.
Antivir Ther.
2012;17(6 Pt B):1147-62.
Abstract
Future perspectives: towards interferon-free regimens for HCV.
Gane E.
Antivir Ther. 2012;17(6 Pt B):1201-10.
Abstract
Highly active anti-hepatitis C therapy: seven lessons from HIV.
Thomas DL.
Antivir Ther. 2012;17(6 Pt B):1183-8.
Abstract
HCV Variants with Decreased Sensitivity to Direct Acting
Antivirals Were Rarely Observed in DAA-Naive Patients Prior to Treatment.
Bartels DJ, Sullivan
JC, Zhang EZ, et al
J Virol. 2012 Nov 14.
Abstract |
The changing face of hepatitis C in the new era of direct-acting
antivirals.
Soriano V, Labarga P,
Fernández-Montero JV, et al
Antiviral Res. 2012 Nov 9.
Abstract
FULL-TEXT
PDF ARTICLE
New therapeutic options for HCV infection in the monoclonal antibody era.
Sautto GA, Diotti RA, Clementi M.
New Microbiol. 2012
Oct;35(4):387-97.
Abstract
Pharmacokinetics of new oral hepatitis C antiviral drugs.
Vispo E, Barreiro P, Soriano V.
Expert Opin Drug Metab Toxicol.
2012 Oct 25.
Abstract
New hepatitis C virus drug discovery strategies and model
systems.
Hussain S, Barretto N, Uprichard SL.
Expert Opin Drug Discov.
2012 Sep;7(9):849-59.
Abstract
Current and emerging antiviral treatments for hepatitis C
infection.
Doyle JS, Aspinall E, Liew D, et al
Br J Clin Pharmacol.
2012 Aug 13.
Abstract
New antiviral therapies in the management of HCV infection.
Farnik H, Zeuzem S.
Antivir Ther. 2012 May 25.
Abstract
Maximizing opportunities and avoiding mistakes in triple therapy for hepatitis
C virus.
Barritt AS 4th, Fried MW
Gastroenterology.
2012 May;142(6):1314-1323.
Abstract
FULL-TEXT ARTICLE
New antiviral agents for hepatitis C.
Pawlotsky JM.
F1000 Biol Rep.
2012;4:5..
Paper |
Antiviral Drugs and the Treatment of
Hepatitis C.
Jalali Z, Rockstroh JK.
Curr HIV/AIDS Rep.
2012 Feb 22
Abstract
Antiviral strategies in hepatitis C virus
infection.
Sarrazin C, Hézode C, Zeuzem S, Pawlotsky JM.
J Hepatol.
2012;56 Suppl:S88-S100
Abstract |
Direct acting antivirals for the treatment of chronic hepatitis
C: one pill a day for tomorrow.
Asselah T, Marcellin P.
Liver Int.2012 Feb;32 Suppl
1:88-102. .
Abstract
FULL-TEXT
ARTICLE
The therapeutic approaches for hepatitis C virus: protease
inhibitors and polymerase inhibitors.
Kwo PY, Vinayek R.
Gut Liver.
2011 Dec;5(4):406-17
Paper |
Provisional Guidance on the Use of Hepatitis
C Virus Protease Inhibitors for Treatment of Hepatitis C
in
HIV-Infected Persons.
Thomas DL, Bartlett JG, Peters MG,
et al
Clin Infect Dis.
2011 Dec 14
Abstract
Recent advance in antiviral drugs for hepatitis C.
Liu J, Shi S, Zhuang H, Luo G.
Zhong Nan Da Xue Xue Bao Yi Xue Ban.
2011 Nov;36(11):1025-36.
Abstract |
Mechanisms Involved in the Development of Chronic Hepatitis
C as Potential Targets of Antiviral Therapy.
Jackowiak P, Figlerowicz M,
Kurzyńska-Kokorniak A, Figlerowicz M.
Curr Pharm Biotechnol. 2011 Sep
9.
Abstract
Oral combination therapy: Future hepatitis C virus
treatment?
Hézode C.
J Hepatol.
2011 May
Abstract
Current drug discovery strategies for treatment of hepatitis C virus infection.
Cheng KC, Gupta S, Wang H,
et al
J Pharm Pharmacol. 2011
Jul;63(7):883-92.
Abstract
Antiviral therapy: why does it fail in HCV-related chronic
hepatitis?
Masarone M, Persico M.
Expert Rev Anti Infect Ther.
2011 May;9(5):535-43..
Abstract
Sustained virologic response to antiviral therapy for chronic
hepatitis C virus infection:
a cure and so much more.
Pearlman BL, Traub N.
Clin Infect Dis.
2011 Apr;52(7):889-900
Abstract
Does the antiviral therapy of patients with chronic
hepatitis exert nephrotoxic effects?
Gluhovschi C, Gadalean F, Kaycsa A, et al
Immunopharmacol Immunotoxicol.
2011 Feb 14
Abstract
Hepatitis C virus Resistance to Protease
Inhibitors.
Halfon P, Locarnini S.
J Hepatol.
2011 Jan 29.
Abstract
Mixing the right hepatitis C inhibitor cocktail.
Gelman MA, Glenn JS.
Trends Mol Med.
2010 Nov 22.
Abstract |
Susceptibility of Treatment-Naive HCV Clinical
Isolates to HCV Protease Inhibitors.
Bae A, Sun SC, Qi X,
et al
Antimicrob Agents Chemother.
2010 Sep 20
Abstract |
Prophylactic antidepressant treatment in patients
with hepatitis C on antiviral therapy:
a double-blind, placebo-controlled trial.
Morasco BJ, Loftis JM, Indest DW,
et
al
Psychosomatics.
2010 Sep;51(5):401-8.
Abstract |
Viral response to specifically targeted antiviral therapy for
hepatitis C
and the implications
for treatment success.
Cooper C.
Can J Gastroenterol.
2010 Jun;24(6):385-90
Abstract |
New directly acting antivirals for hepatitis C:
potential for interaction with antiretrovirals.
Seden K, Back D, Khoo S.
J Antimicrob
Chemother.
2010 Mar 23
Abstract |
Antiviral therapy reduces risk of hepatocellular carcinoma in patients with
hepatitis C
virus-related cirrhosis.
Singal AK, Singh A, Jaganmohan et al
Clin Gastroenterol Hepatol. 2009 Oct 29
Abstract |
Compound Chinese herbal medicines, Chinese herbal drugs and their active
extracts for treatment
of chronic hepatitis C: a systematic review and meta-analysis of randomized
clinical trials
Qin XK, Han M, Liu JP.
Zhong Xi Yi Jie He Xue Bao. 2009
Oct;7(10):913-28.
Abstract |
Long-term effectiveness and cost-effectiveness of antiviral
treatment in hepatitis C.
Sroczynski G, Esteban E, Conrads-Frank A,, et a;
J Viral Hepat.
2009
Jul 28.
Abstract |
New and experimental therapies for HCV.
Pereira AA, Jacobson IM.
Nat Rev Gastroenterol Hepatol.
2009 Jul;6(7):403-11.
Abstract |
Decline in Male Sexual Desire, Function, and
Satisfaction During and
After Antiviral Therapy for Chronic
Hepatitis C.
Dove LM, Rosen RC, Ramcharran D, et al
Gastroenterology.
2009 Jun 12.
Abstract |
Antiviral resistance and specifically targeted
therapy for HCV (STAT-C).
Thompson AJ, McHutchison JG.
J Viral Hepat.
2009 Jun;16(6):377-87
Abstract |
|
New drug targets for hepatitis C and other flaviviridae viruses.
Paula T, Pablo R, Eugenia V, et al
Infect Disord Drug Targets.
2009 Mar;9(2)
Abstract
|
The impact of antiviral treatments on the course of chronic
hepatitis C: an evidence-based
approach.
Camma C, Di Bona D, Craxi A.
Curr Pharm Des. 2004;10(17):2123-30.
Abstract
|
Conference Reports, Abstracts, and
Posters
|
Journal Papers, Abstracts, and
Commentaries
Journal Papers, Abstracts, and
Commentaries
| |
|
Boceprevir: A recently approved protease inhibitor for hepatitis
C virus infection.
Lam JT, Jacob S.
Am J Health Syst Pharm.
2012 Dec 15;69(24):2135-9.
Abstract
Boceprevir in combination with HIV protease inhibitors in
patients with advanced fibrosis-altered drug-drug interactions?
Schwarze-Zander C, Boesecke C,
et al
J Int AIDS Soc.
2012 Nov 11;15(6):18418.
Abstract
Boceprevir and personalized medicine in hepatitis C virus
infection.
Habersetzer F, Leboeuf C, Doffoël M, Baumert TF.
Pharmgenomics Pers Med.
2012;5:125-37
Abstract
Stereoselective Addition of 2-phenyloxazol-4-yl
trifluoromethanesulfonate to N-Sulfinyl Imines: Application to the Synthesis of
the HCV Protease Inhibitor Boceprevir.
Morris WJ, Muppalla KK, Cowden C, Ball RG.
J Org Chem. 2012 Dec 6
Abstract
The first wave: HCV NS3 protease inhibitors telaprevir and
boceprevir.
Marks KM, Jacobson IM.
Antivir Ther. 2012;17(6 Pt
B):1119-31.
Abstract
A WEEK-IN REVIEW FEATURED REPORT
Pharmacokinetic Interactions Between the HCV Protease Inhibitor Boceprevir and
Ritonavir-Boosted HIV-1 Protease Inhibitors Atazanavir, Darunavir, and
Lopinavir.
Hulskotte EG, Feng HP, Xuan F,
et al
Clin Infect Dis. 2012 Nov 15.
Abstract |
A WEEK-IN-REVIEW
FEATURED
REPORT
The Relative Efficacy of Boceprevir and Telaprevir in the
Treatment of HCV Genotype 1.
Schmitz S, O'Leary A, Walsh C, Bergin C, Norris S.
Clin Infect Dis. 2012 Oct
16.
Abstract
Pharmacokinetic Interaction between Boceprevir and Etravirine in
HIV/HCV Seronegative Volunteers.
Hammond KP, Wolfe P, Burton JR Jr, :
J Acquir Immune Defic Syndr. 2012 Oct 15
Abstract
A WEEK-IN-REVIEW FEATURED
REPORT
Boceprevir: A Protease Inhibitor for the Treatment of Hepatitis
C.
Chang MH, Gordon LA, Fung HB.
Clin Ther. 2012 Sep 10.
Abstract
Practical Management of Boceprevir and Immunosuppressive Therapy in Liver
Transplant Recipient Recurrence
Coilly A, Furlan V, Roche B, et al
Antimicrob Agents Chemother.2012
Aug 29
Abstract
Triple therapy with boceprevir or telaprevir for treatment naïve
HCV patients.
Esteban R, Buti M.
Best Pract Res Clin Gastroenterol.
Abstract
Triple therapy with boceprevir or telaprevir for prior HCV non-responders.
Asselah T.
Best Pract Res Clin Gastroenterol.
2012 Aug;26(4):455-62
Abstract
The first wave: HCV NS3 protease inhibitors telaprevir and boceprevir.
Marks KM, Jacobson IM.
Antivir Ther. 2012;17(6 Pt
B):1119-31.
Abstract
A WEEK-IN-REVIEW FEATURED REPORT
Factors that Predict Response of Patients with HCV
Infection to Boceprevir.
Poordad F, Bronowicki JP, Gordon SC, et al
Gastroenterology. 2012 May 21
Abstract |
Review of boceprevir and telaprevir for the treatment
of chronic hepatitis C.
Wilby KJ, Partovi N, Ford JA, Greanya E, Yoshida EM.
Can J Gastroenterol.
2012 Apr;26(4):205-10.
Abstract
A WEEK-IN-REVIEW FEATURED REPORT
Boceprevir: an oral protease inhibitor for the treatment of chronic HCV
infection.
Trembling PM, Tanwar S, Dusheiko GM.
Expert Rev Anti Infect Ther. 2012 Mar;10(3):269-79.
Abstract
A WEEK-IN-REVIEW FEATURED REPORT
A review of drug interactions with boceprevir and
telaprevir: implications for HIV and transplant patients.
Wilby KJ, Greanya ED, Ford JA,, et al
Ann Hepatol.
2012 Mar;11(2):179-85.
Abstract |
Expert opinion on boceprevir- and telaprevir-based triple
therapies of chronic hepatitis C.
Sarrazin C, Berg T, Cornberg M,
et al
Z Gastroenterol. 2012
Jan;50(1):57-72.
Abstract
A WEEK-IN-REVIEW FEATURED REPORT
Triple therapy for HCV genotype 1 infection:
telaprevir or boceprevir?
Shiffman ML, Esteban R.
Liver Int. 2012
Feb;32 Suppl 1:54-60.
Abstract
Phase III results of Boceprevir in treatment naïve
patients with chronic hepatitis C genotype 1
Manns MP, Markova AA, Serrano BC, Cornberg M.
Liver Int. 2012 Feb;32
Suppl 1:27-31.
Abstract |
Specific Detection of Naturally Occurring Telaprevir
and Boceprevir (Protease Inhibitors)
HCV Resistant Mutants
among Treatment Naive Infected Individuals.
Fonseca-Coronado S, Escobar-Gutiérrez A, Ruiz-Tovar K,
et al
J Clin Microbiol.
2011 Nov 23.
Abstract
Formulary management of the protease inhibitors boceprevir
and telaprevir for chronic hepatitis C virus.
Tungol A, Rademacher K, Schafer JA.
J Manag Care Pharm. 2011
Nov;17(9):685-94.
Abstract |
A WEEK-IN-REVIEW FEATURED REPORT
Analysis of long-term persistence of resistance
mutations within the hepatitis C virus NS3 protease
after treatment with telaprevir or boceprevir.
Susser S, Vermehren J, Forestier N,
et al
J Clin Virol.
2011 Sep 14.
Abstract
A
WEEK-IN-REVIEW FEATURED REPORT
Boceprevir: A Protease Inhibitor for the Treatment of
Chronic Hepatitis C (September).
Foote BC, Spooner LM, Belliveau PP.
Ann Pharmacother.
2011 Aug 9
Abstract
A sprint to increase response to HCV treatment:
expectancies but caution.
Asselah T.
J Hepatol. 2011 Jun 30
Abstract
Efficacy of boceprevir, an NS3 protease inhibitor, in combination with
peginterferon alfa-2b
and ribavirin in treatment-naive patients with genotype 1 hepatitis C
infection (SPRINT-1):
an open-label, randomised, multicentre phase 2 trial.
Kwo PY, Lawitz EJ, McCone J,.
et al
Lancet.
2010 Aug 28;376(9742):705-16
Abstract
Highly sensitive determination of HCV protease inhibitors
boceprevir (SCH 503034) and
telaprevir (VX 950) in human plasma by LC-MS/MS.
Farnik H, El-Duweik J, Welsch C,
J Chromatogr B Analyt
Technol Biomed Life Sci.
2009 Dec 1;877(31):4001
Abstract |
Conference Reports, Abstracts, and
Posters
| |
|
POSTER
The
Influence of the HCV Protease Inhibitor Boceprevir on the Pharmacokinetics of
the HIV Integrase I
nhibitor Raltegravir
C de Kanter, M Blonk, A
Colbers, et al
(19 CROI)
PDF Poster
Abstract
|
POSTER
Pharmacokinetic Interaction between the HCV Protease Inhibitor Boceprevir and
Ritonavir-boosted HIV-1
Protease Inhibitors Atazanavir, Lopinavir, and Darunavir
E Hulskotte, H-P Feng, F
Xuan, et al
(19 CROI)
PDF Poster
Abstract
|
POSTER
Frequencies of Resistance-associated
Amino Acid Variants following Combination
Treatment with BOC + P/R in Patients with Chronic HCV, Genotype-1
R Barnard L Pedicone, E Chaudhri, et al
(18 CROI)
PDF Poster
Abstract
HCV
RESPOND-2 Final Results: High Sustained Virologic Response among
Genotype-1
Previous Non-responders and Relapsers to pegIFN/RBV when
Re-treated with BOC +
PEGINTRON/RBV
S Gordon, B Bacon, E Lawitz,
et al
(18 CROI)
Abstract
BOC Combined with P/R for Treatment-naïve Patients
with HCV Genotype-1: SPRINT-2 Final Results
M Sulkowski, F Poordad, J
McCone, et al
18 CROI)
Abstract |
Journal Papers, Abstracts, and
Commentaries
Journal Papers,
Abstracts, and Commentaries
|
|
General
Reports
Amantadine